NCT03105726

Medical Care Versus Ventricular Assist Device for the Management of End-stage Heart Failure (MEVADE)

Medical Care Versus Ventricular Assist Device in Patients With NYHA Class IV Congestive Heart Failure: a Non Randomized Comparison of Clinical and Economic Outcomes

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 224 (actual)
• Sponsor: Joe Elie Salem · Academic / Other
• Sex: All
• Age: 18 Years – 76 Years
• Healthy volunteers: Not accepted

Summary

End-stage heart failure (ESHF) represents a major burden in terms of quality of life, mortality and costs. The current practice in France is to treat patients with ESHF by a combination of drugs and lifestyle interventions before proposing heart transplant (HT) if there is no contraindication. In the Heart and Diabetes Center of Bad Oyenhausen (BO) in Germany, patients presenting with ESHF are preferentially managed by ventricular assist device (VAD) therapy. The primary purpose of this study was to compare the outcomes of these two strategies in the management of ESHF and associated consumption of resources.

Conditions

• Heart Failure
• Heart Transplantation
• Heart-Assist Devices

Timeline

• Start date: 2010-11-01
• Primary completion: 2013-10-01
• Completion: 2014-01-01
• First posted: 2017-04-10
• Last updated: 2017-04-27